Performance comparison between Elecsys Anti-SARS-CoV-2 and Anti-SARS-CoV-2 S and Atellica IM SARS-CoV-2 Total and SARS-CoV-2 IgG assays

다국어 초록 (Multilingual Abstract)

Background: Although serological severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) tests from several manufacturers have been introduced in South Korea and some are commercially available, the performance of these test kits has not yet been sufficiently validated. Therefore, we compared the performance of Elecsys Anti-SARS-CoV-2 (ACOV2) and Anti-SARS-CoV-2 S (ACOV2S) and Atellica IM SARS-CoV-2 Total (COV2T) and SARS-CoV-2 IgG (sCOVG) serological tests in this study.Methods: A total of 186 patient samples were used. For each test, we analyzed the positive rate of serological antibody tests, precision, linearity, and agreement among the four assays.Results: The positive rates of COV2T, sCOVG, and ACOV2S were high (81.7%–89.2%) in total, with those for ACOV2S being the highest, while those of ACOV2 were as low as 44.6%. This may be related to the high completion rate of vaccination in Korea. The repeatability and within-laboratory coefficients of variation were within the claimed allowable imprecision; however, further research is needed to establish an allowable imprecision at low concentrations. COV2T showed a linear fit, whereas sCOVG and ACOV2S were appropriately modeled with a nonlinear fit. Good agreement was found among COV2T, sCOVG, and ACOV2S; however, the agreement between ACOV2 and any one of the other methods was poor.Conclusions: Considering the different antigens used in serological SARS-CoV-2 antibody assays, the performance of the tested assays is thought to show no significant difference for the qualitative detection of antibodies to SARS-CoV-2.

참고문헌 (Reference)

1 Ye ZW, "Zoonotic origins of human coronaviruses" 16 : 1686-1697, 2020

2 Jolobe OMP, "What are the criteria for asymptomatic status?" 114 : 351-352, 2021

3 Giavarina D, "Understanding Bland Altman analysis" 25 : 141-151, 2015

4 Safiabadi Tali SH, "Tools and techniques for severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)/COVID-19 detection" 34 : e00228–20-, 2021

5 Du L, "The spike protein of SARS-CoV : a target for vaccine and therapeutic development" 7 : 226-236, 2009

6 Landis JR, "The measurement of observer agreement for categorical data" 33 : 159-174, 1977

7 Bland JM, "Statistical methods for assessing agreement between two methods of clinical measurement" 1 : 307-310, 1986

8 Pal M, "Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): an update" 12 : e7423-, 2020

9 Xu X, "Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China" 26 : 1193-1195, 2020

10 Nakagama Y, "Serological testing reveals the hidden COVID-19 burden among health care workers experiencing a SARS-CoV-2 nosocomial outbreak" 9 : e0108221-, 2021

11 Kadam SB, "SARS-CoV-2, the pandemic coronavirus : Molecular and structural insights" 61 : 180-202, 2021

12 Stegeman I, "Routine laboratory testing to determine if a patient has COVID-19" 11 : CD013787-, 2020

13 LeBlanc JJ, "Real-time PCR-based SARS-CoV-2 detection in Canadian laboratories" 128 : 104433-, 2020

14 Florin L, "Performance evaluation of the Siemens SARS-CoV-2 Total Antibody and IgG Antibody Test" 52 : e147-3, 2021

15 Tiwari N, "Novel β-coronavirus(SARS-CoV-2) : current and future aspects of pharmacological treatments" 28 : 1243-1252, 2020

16 Hwang YC, "Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection" 29 : 1-, 2022

17 Trougakos IP, "Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications" 28 : 9-, 2021

18 Bhimraj A, "Infectious Diseases Society of America Guidelines on the treatment and management of patients with COVID-19" 2020

19 Giavarina D, "Improvements and limits of anti SARS-CoV-2 antibodies assays by WHO(NIBSC 20/136)standardization" 9 : 274-279, 2021

20 Xu H, "High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa" 12 : 8-, 2020

21 Letko M, "Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses" 5 : 562-569, 2020

22 Saputri DS, "Flexible, functional, and familiar : characteristics of SARS-CoV-2 spike protein evolution" 11 : 2112-, 2020

23 Tholen DW, "Evaluation of the linearity of quantitative measurement procedures: a statistical approach; approved guideline" Clinical and Laboratory Standards Institute 2003

24 Moura DTH, "Diagnostic characteristics of serological-based COVID-19 testing: a systematic review and meta-analysis" 75 : e2212-, 2020

25 Gao J, "Current status of diagnostic testing for SARS-CoV-2 infection and future developments : a review" 26 : e928552-, 2020

26 Nittari G, "Current pharmacological treatments for SARS-COV-2 : a narrative review" 882 : 173328-, 2020

27 Haselmann V, "Comparison of test performance of commercial anti-SARS-CoV-2 immunoassays in serum and plasma samples" 510 : 73-78, 2020

28 Leuzinger K, "Comparing immunoassays for SARS-CoV-2 antibody detection in patients with and without laboratory-confirmed SARS-CoV-2 infection" 59 : e0138121-, 2021

29 Kim Min-Kyung ; Lee Bora ; Choi Youn Young ; Um Jihye ; Lee Kyung-Shin ; Sung Ho Kyung ; Kim Yeonjae ; Park Jun-Sun ; Lee Myungsun ; Jang Hee-Chang ; Bang Ji Hwan ; Chung Ki-hyun ; Jeon Jaehyun, "Clinical Characteristics of 40 Patients Infected With the SARS-CoV-2 Omicron Variant in Korea" 대한의학회 37 (37): 1-5, 2022

30 Kim Mi-Ae ; Lee Yong Won ; 김소리 ; 김주희 ; 민택기 ; 박해심 ; 신미용 ; 예영민 ; 이수영 ; 이종민 ; 최정희 ; 장광천 ; 장윤석, "COVID-19 Vaccine-associated Anaphylaxis and Allergic Reactions: Consensus Statements of the KAAACI Urticaria/Angioedema/Anaphylaxis Working Group" 대한천식알레르기학회 13 (13): 526-544, 2021

31 Aguirre JJ, "Application of the CLSI EP15-A3 guideline as an alternative troubleshooting tool for verification of assay precision" 152 (152): S88-, 2019

32 Igawa G, "Antibody response and seroprevalence in healthcare workers after the BNT162b2 vaccination in a University Hospital at Tokyo" 12 : 8707-, 2022

33 Zhou P, "A pneumonia outbreak associated with a new coronavirus of probable bat origin" 579 : 270-273, 2020